Rockwell Medical Technologies (NASDAQ: RMTI) reported Q4 EPS of ($0.10), $0.01 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $13.4 million versus the consensus estimate of $12.01 million.

• Sales were $13.4 million, or $0.7 million lower than Q4 2015, primarily due to lower domestic and lower contract manufacturing concentrate sales.
• Gross profit was $2.0 million compared to $2.1 million in Q4 2015.
• SG&A expense was $6.0 million compared $6.1 million in Q4 2015.
• R&D expense was $1.2 million compared to $2.0 million in Q4 2015.
• Net loss was $5.1 million or ($0.10) per share compared to a $5.8 million loss or ($0.12) per share in Q4 2015. Net loss was $0.7 million less year over year primarily due to lower R&D expense of $0.8 million.
• Cash and investments were $57.9 million as of December 31, 2016.
• Net working capital was $68.4 million as of December 31, 2016.

For earnings history and earnings-related data on Rockwell Medical Technologies (RMTI) click here.